A Rapid, Non-Invasive Fluorescence-Based Urinary Exfoliated Cell Assay as an Adjunctive Diagnostic Test for Urothelial Carcinoma in Patients with Hematuria: A Prospective Diagnostic Study

Background Hematuria often prompts investigation for urinary malignancy, but cystoscopy is invasive and resource-dependent. We evaluated a rapid fluorescence urinary exfoliated-cell assay as an auxiliary test for urothelial carcinoma (UC) in patients with hematuria. Methods In this single-center prospective diagnostic study (Ruijin Hospital, April–July 2026), 94 patients were analyzed after exclusions. All underwent fluorescence staining; DNA ploidy (n = 81) and hematoxylin and eosin (H&E) staining (n = 80) were comparators. Histopathology was the reference standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 95% confidence intervals (CIs), Kappa, and paired McNemar tests were calculated. Results There were 55 UC and 39 benign cases. Fluorescence sensitivity was 70.9% (95% CI 57.9–81.2), specificity 76.9% (61.6–87.4), PPV 81.3%, NPV 65.2%, and Kappa 0.466. DNA ploidy sensitivity was 24.5%, specificity 100%, and NPV 41.2%; H&E sensitivity was 23.1%, specificity 100%, and NPV 41.2%. Fluorescence was more sensitive than both comparators (P < 0.001); DNA ploidy and H&E did not differ (P = 1.0). Limitations include single-center design, small subgroups, 26/131 quality-control exclusions, non-random missing comparators, few upper tract cases, and an unvalidated RNA mechanism. Conclusions The assay is auxiliary, not a replacement. Negative fluorescence cannot exclude UC; high-risk patients need cystoscopy and upper tract evaluation. Multicenter validation is required. Trial registration: ClinicalTrials.gov NCT07813260, retrospectively registered on September 2026.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11557249/v1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A Rapid, Non-Invasive Fluorescence-Based Urinary Exfoliated Cell Assay as an Adjunctive Diagnostic Test for Urothelial Carcinoma in Patients with Hematuria: A Prospective Diagnostic Study

Danfeng Xu, Yulai Liu, Kaihan Dai, Hanqing Xiao et al.
Research Square
Bladder and Urothelial Cancer Treatments
preprint

A Rapid, Non-Invasive Fluorescence-Based Urinary Exfoliated Cell Assay as an Adjunctive Diagnostic Test for Urothelial Carcinoma in Patients with Hematuria: A Prospective Diagnostic Study

Danfeng Xu, Yulai Liu, Kaihan Dai, Hanqing Xiao, Liqi Yi, shangfan liao, xi liu, yi gao, luoping zheng, hai huang
preprint en

Abstract

Background Hematuria often prompts investigation for urinary malignancy, but cystoscopy is invasive and resource-dependent. We evaluated a rapid fluorescence urinary exfoliated-cell assay as an auxiliary test for urothelial carcinoma (UC) in patients with hematuria. Methods In this single-center prospective diagnostic study (Ruijin Hospital, April–July 2026), 94 patients were analyzed after exclusions. All underwent fluorescence staining; DNA ploidy (n = 81) and hematoxylin and eosin (H&E) staining (n = 80) were comparators. Histopathology was the reference standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 95% confidence intervals (CIs), Kappa, and paired McNemar tests were calculated. Results There were 55 UC and 39 benign cases. Fluorescence sensitivity was 70.9% (95% CI 57.9–81.2), specificity 76.9% (61.6–87.4), PPV 81.3%, NPV 65.2%, and Kappa 0.466. DNA ploidy sensitivity was 24.5%, specificity 100%, and NPV 41.2%; H&E sensitivity was 23.1%, specificity 100%, and NPV 41.2%. Fluorescence was more sensitive than both comparators (P < 0.001); DNA ploidy and H&E did not differ (P = 1.0). Limitations include single-center design, small subgroups, 26/131 quality-control exclusions, non-random missing comparators, few upper tract cases, and an unvalidated RNA mechanism. Conclusions The assay is auxiliary, not a replacement. Negative fluorescence cannot exclude UC; high-risk patients need cystoscopy and upper tract evaluation. Multicenter validation is required. Trial registration: ClinicalTrials.gov NCT07813260, retrospectively registered on September 2026.

Research Square
Ruijin Hospital (CN), Sanming University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Fujian Province
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon